Medicus Pharma Submits FDA Plan for Novel Equine Cancer Treatment

An update from Medicus Pharma Ltd ( (MDCX) ) is now available.

Medicus Pharma Ltd. has submitted a product development plan to the FDA for their D-MNA patch, aimed at treating external squamous cell carcinoma in horses. This submission follows their receipt of a Minor Use in Major Species Designation, which could grant them a seven-year exclusive marketing period upon approval. The D-MNA patch represents a non-invasive treatment option in a market with limited veterinary oncology drugs, potentially providing Medicus with a first-mover advantage. The clinical study will assess the efficacy of the D-MNA patch in a randomized, double-blind, placebo-controlled trial involving 50 horses, with promising results from previous human trials supporting its safety and efficacy.

The most recent analyst rating on (MDCX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Spark’s Take on MDCX Stock

According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform.

Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.

To see Spark’s full report on MDCX stock, click here.

More about Medicus Pharma Ltd

Medicus Pharma Ltd. is a company operating in the veterinary oncology industry, focusing on developing innovative treatments for animal cancers. Their primary product is a novel doxorubicin-containing microneedle array (D-MNA) patch, designed to treat external squamous cell carcinoma (SCC) in horses. The company is targeting a niche market with significant unmet needs, potentially valued at $250 million.

Average Trading Volume: 184,032

Current Market Cap: $43.7M

Find detailed analytics on MDCX stock on TipRanks’ Stock Analysis page.